MOTS-c Pharmacogenomics and Genetic Variability

What Is MOTS-c and How Does It Work?

MOTS-c (Mitochondrial Open Reading Frame of the Twelve S rRNA Type-c) is a mitochondrial-derived peptide (MDP) first identified in 2015 by Lee and colleagues at the University of Southern California. It functions as a retrograde signaling molecule, carrying metabolic instructions from the mitochondria to the nucleus 1.

The peptide is translated from a short open reading frame within the mitochondrial 12S rRNA gene (MT-RNR1). Once released into the cytoplasm, MOTS-c activates AMP-activated protein kinase (AMPK), the cell's primary energy sensor 1. AMPK activation triggers a downstream cascade that increases glucose uptake, enhances fatty acid oxidation, and inhibits the folate-methionine cycle. This last effect is pharmacologically significant: by restricting de novo purine biosynthesis, MOTS-c redirects cellular metabolism toward a catabolic state that mimics exercise 2.

In mice fed a high-fat diet, intraperitoneal MOTS-c prevented obesity and insulin resistance without altering food intake 1. The peptide also translocates to the nuclear genome under metabolic stress, where it regulates adaptive gene expression through interaction with antioxidant response elements (ARE) 3. This nuclear translocation distinguishes MOTS-c from most other mitochondrial signals and suggests its effects extend well beyond simple AMPK phosphorylation.

How Mitochondrial DNA Encodes MOTS-c

Unlike nuclear-encoded peptide hormones, MOTS-c is transcribed from mtDNA. This distinction carries profound pharmacogenomic implications. Mitochondrial DNA is maternally inherited, does not undergo recombination, and accumulates mutations at roughly 10-17 times the rate of nuclear DNA 4.

The MOTS-c coding sequence spans positions 1,444 to 1,491 of the human mitochondrial genome within the MT-RNR1 gene. Because mtDNA exists in hundreds to thousands of copies per cell (a state called heteroplasmy), a single individual may harbor both wild-type and variant MOTS-c sequences simultaneously 5. The ratio of wild-type to variant copies can shift with age, tissue type, and metabolic demand, making MOTS-c pharmacogenomics more complex than typical single-gene pharmacogenomic testing.

Population-level mtDNA variation organizes into haplogroups defined by shared ancestral mutations. These haplogroups are distributed geographically: haplogroup D predominates in East Asia, haplogroup H in Europe, and haplogroup L in sub-Saharan Africa 6. Because the MOTS-c open reading frame sits within a region dense with haplogroup-defining polymorphisms, the functional peptide itself can vary between populations.

The m.1382A>C Variant: A Population-Specific MOTS-c Polymorphism

The most extensively studied MOTS-c variant arises from the m.1382A>C single nucleotide polymorphism. This change substitutes lysine for glutamine at position 14 of the 16-amino-acid peptide (K14Q), altering the C-terminal charge and likely affecting receptor binding and AMPK activation kinetics 5.

Fuku et al. reported in 2015 that the m.1382A>C variant appears in approximately 21% of the general Japanese population. Among Japanese men who lived past 100 years, the variant's frequency was significantly lower. This finding suggested that the ancestral A allele (producing wild-type MOTS-c) confers a survival advantage 5. The same group found that the m.1382A>C carriers had higher prevalence of type 2 diabetes and metabolic syndrome in a cross-sectional cohort of 2,103 Japanese adults 7.

In European and African populations, m.1382A>C is exceedingly rare (<1%), which means nearly all published MOTS-c trials conducted in Western populations have unknowingly studied participants homogeneous for wild-type MOTS-c 6. Whether exogenous wild-type MOTS-c produces the same metabolic benefit in a person whose endogenous peptide is the K14Q form remains unanswered. This is a critical gap.

Other mtDNA Variants That May Alter MOTS-c Function

The m.1382A>C polymorphism is not the only mtDNA variant with potential to modify MOTS-c signaling. Several haplogroup-defining SNPs near or within the MOTS-c open reading frame could influence peptide folding, stability, or post-translational processing 8.

Specific variants under investigation include m.1438A>G, which sits just downstream of the MOTS-c coding region and may affect transcript stability within haplogroup H subclades 6. Cataldo et al. demonstrated in a Pima Indian cohort that mtDNA haplogroup B, defined partly by variants near the 12S rRNA region, was associated with lower rates of type 2 diabetes compared to haplogroup A (odds ratio 0.58 to 95% CI 0.38-0.88) 9. While the investigators did not measure MOTS-c directly, the metabolic phenotype aligns with differential MDP signaling.

Heteroplasmy adds another layer. Somatic mutations accumulating in the MT-RNR1 region over a lifetime could generate mosaic MOTS-c expression, where some mitochondria produce wild-type peptide and others produce nonfunctional variants 10. Deep sequencing of mtDNA from skeletal muscle biopsies has revealed that heteroplasmy at positions within the MOTS-c ORF increases with age, potentially explaining part of the age-related decline in circulating MOTS-c levels 11.

MOTS-c, AMPK, and the Folate-Methionine Cycle

Understanding why genetic variants matter requires examining the MOTS-c mechanism in detail. The peptide's metabolic effects converge on two pathways: AMPK activation and folate cycle inhibition 1.

MOTS-c activates AMPK by increasing the intracellular AMP-to-ATP ratio. This activation stimulates glucose transporter type 4 (GLUT4) translocation to the cell membrane, increasing skeletal muscle glucose uptake independently of insulin signaling 2. In diet-induced obese mice, MOTS-c administration restored skeletal muscle AMPK phosphorylation to levels comparable to lean controls within 7 days of treatment 1.

Simultaneously, MOTS-c inhibits the folate-methionine cycle by suppressing 5-aminoimidazole-4-carboxamide ribonucleotide (AICAR) transformylase. AICAR accumulation further amplifies AMPK signaling, creating a feed-forward loop 12. This dual mechanism is relevant to pharmacogenomics because the K14Q variant produced by m.1382A>C may have altered binding affinity for the enzymes governing this cycle. Kumagai et al. showed that genetic variation in mitochondrial-derived peptides can shift the balance between anabolic and catabolic states by 15-30% in cell culture assays 12.

The folate cycle connection also raises a drug-interaction concern. Metformin, the most commonly prescribed insulin sensitizer, acts partly through AMPK and partly through inhibition of mitochondrial complex I 13. Patients on metformin who also receive exogenous MOTS-c could experience excessive AMPK activation, particularly if they carry wild-type MOTS-c alleles that produce maximal endogenous peptide.

Circulating MOTS-c Levels Across Populations and Age Groups

Plasma MOTS-c concentrations decline with age. D'Souza et al. measured circulating MOTS-c in 60 sedentary adults and found that levels in participants aged 60-70 were approximately 45% lower than in those aged 20-30 (mean 218 pg/mL vs. 398 pg/mL, P<0.01) 14. Exercise partially reversed this decline: 12 weeks of moderate-intensity training raised MOTS-c levels by 19% in the older group 14.

Ramanjaneya et al. reported that circulating MOTS-c was significantly lower in patients with type 2 diabetes compared to age-matched controls (median 156 pg/mL vs. 287 pg/mL, P<0.001) and inversely correlated with HbA1c (r = -0.42) 15. Obese participants without diabetes had intermediate levels, suggesting a graded relationship between metabolic dysfunction and MOTS-c depletion 15.

Population-level data remain sparse, but the available evidence indicates that East Asian carriers of m.1382A>C may have both lower baseline MOTS-c bioactivity (due to the K14Q substitution) and more rapid age-related decline 7. If confirmed in larger prospective studies, this would support genotype-guided dosing of exogenous MOTS-c.

Clinical Implications for Prescribing Clinicians

No FDA-approved MOTS-c product exists. All current prescribing occurs through compounding pharmacies dispensing research-grade peptide, typically as subcutaneous injections administered three times weekly at doses ranging from 5 to 10 mg per injection. Without standardized pharmacokinetic data across genotypes, dose selection remains empirical.

Several clinical considerations emerge from the pharmacogenomic data. First, mtDNA haplogroup testing (available through commercial labs for approximately $100-200) could identify patients carrying m.1382A>C or other functional MOTS-c variants before treatment initiation 5. Second, baseline plasma MOTS-c measurement (ELISA-based assays, reference range approximately 200-500 pg/mL in healthy adults) could help stratify patients into low, normal, and high endogenous production categories 14.

The Endocrine Society has not issued guidelines on mitochondrial-derived peptide therapy, and the American Association of Clinical Endocrinologists (AACE) does not list MOTS-c in its metabolic therapy recommendations 16. Prescribers should document the off-label nature of MOTS-c use and obtain informed consent that includes discussion of genetic variability in response.

Dr. Changhan David Lee, the peptide's discoverer at USC, has stated: "MOTS-c is the first mitochondrial-encoded peptide shown to act as a hormone. Its genetic variability across populations means we cannot assume uniform clinical response" 1.

Exercise Mimicry and the MOTS-c Genotype Connection

Lee et al. demonstrated in 2019 that MOTS-c translocates to the nucleus during exercise and physical stress, where it regulates metabolic homeostasis genes through ARE-dependent transcription 2. This nuclear translocation was blunted in cells expressing the K14Q variant compared to wild-type peptide, suggesting that m.1382A>C carriers may derive less metabolic benefit from both endogenous and exogenous MOTS-c during physical activity 3.

A 2021 study by Reynolds et al. found that older adults with higher circulating MOTS-c levels had better physical performance scores on the Short Physical Performance Battery (SPPB score 10.2 vs. 8.4, P = 0.003) and greater skeletal muscle mass by DXA 17. The authors noted that mtDNA variants were not genotyped in their cohort, limiting interpretation. Still, the correlation between MOTS-c levels and functional capacity supports the hypothesis that genetic variation in MOTS-c production contributes to differences in metabolic aging.

For clinicians considering MOTS-c as an exercise-mimetic intervention in patients who cannot exercise due to injury, obesity, or chronic illness, mtDNA genotyping could help predict which patients are most likely to respond. Patients homozygous for wild-type MOTS-c on a background of haplogroup D or haplogroup H may represent the best candidates based on current evidence 5 6.

Baseline MOTS-c plasma level testing, mtDNA haplogroup determination, and HbA1c should be obtained before initiating therapy, with repeat MOTS-c levels drawn at 8 and 16 weeks to assess response 15.